- Home
- PMVP vs ASRT Comparison
PMVP vs ASRT Comparison
Compare PMVP & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- ASRT
- Stock Information
- Founded
- PMVP 2013
- ASRT 1995
- Country
- PMVP United States
- ASRT United States
- Employees
- PMVP N/A
- ASRT N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- ASRT Health Care
- Exchange
- PMVP Nasdaq
- ASRT Nasdaq
- Market Cap
- PMVP 62.3M
- ASRT 57.9M
- IPO Year
- PMVP 2020
- ASRT 1997
- Fundamental
- Price
- PMVP $1.34
- ASRT $0.66
- Analyst Decision
- PMVP Strong Buy
- ASRT Strong Buy
- Analyst Count
- PMVP 1
- ASRT 2
- Target Price
- PMVP $5.00
- ASRT $3.25
- AVG Volume (30 Days)
- PMVP 239.6K
- ASRT 239.8K
- Earning Date
- PMVP 08-07-2025
- ASRT 08-06-2025
- Dividend Yield
- PMVP N/A
- ASRT N/A
- EPS Growth
- PMVP N/A
- ASRT N/A
- EPS
- PMVP N/A
- ASRT N/A
- Revenue
- PMVP N/A
- ASRT $119,001,000.00
- Revenue This Year
- PMVP N/A
- ASRT N/A
- Revenue Next Year
- PMVP N/A
- ASRT $11.91
- P/E Ratio
- PMVP N/A
- ASRT N/A
- Revenue Growth
- PMVP N/A
- ASRT N/A
- 52 Week Low
- PMVP $0.81
- ASRT $0.51
- 52 Week High
- PMVP $1.82
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- PMVP 72.39
- ASRT 49.02
- Support Level
- PMVP $0.96
- ASRT $0.63
- Resistance Level
- PMVP $1.36
- ASRT $0.73
- Average True Range (ATR)
- PMVP 0.09
- ASRT 0.03
- MACD
- PMVP 0.02
- ASRT 0.00
- Stochastic Oscillator
- PMVP 95.31
- ASRT 36.64
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.